Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients

Psychoneuroendocrinology

Volumn 29, Issue 4, 2004, Pages 448-474

  Carlson, Linda E ^a,b   Speca, Michael ^a,b   Patel, Kamala D ^b   Goodey, Eileen ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cancer; Cortisol; DHEAS; Meditation; Melatonin; MSBR; Psychoneuroendocrinology; Quality of life; Stress

Indexed keywords

HYDROCORTISONE; MELATONIN; PRASTERONE SULFATE;

ADULT; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; HEALTH BEHAVIOR; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEISURE; MAJOR CLINICAL STUDY; MALE; MEDITATION; MOOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; STRESS; SYMPTOMATOLOGY; YOGA;

EID: 1642430919     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(03)00054-4     Document Type: Article

References (88)

1. Aaronson N.K., Ahmedzai S., Bullinger M., Crabeels D., Estape J., Filiberti A., Flechtner H., Frick U., Hurny C., Kaasa S., Klee M., Mastilica M., Osoba D., Pfausler B., Razavi D., Rofe P.B., Schraub S., Sullivan M., Takeda F. The EORTC core quality of life questionnaire: interim results of an international field study. Osoba D. Effect of Cancer on Quality of Life. 1991;185-203 CRC Press, London.
2. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., deHaes J.C.J.M., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P.B., Schraub S., Sneeuw K., Sullivan M., Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:1993;365-376.
3. Andersen B.L., Kiecolt-Glaser J.K., Glaser R. A biobehavioral model of cancer stress and disease course. Am. Psychol. 49:(5):1994;389-404.
4. Aragona M., Muscatello M.R., Losi E., Panetta S., La T.F., Pastura G., Bertolani S., Mesiti M. Lymphocyte number and stress parameter modifications in untreated breast cancer patients with depressive mood and previous life stress. J. Exp. Ther. Oncol. 1:(6):1996;354-360.
5. Bartsch C., Bartsch H., Fluchter S.H., Attanasio A., Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J. Pineal Res. 2:(2):1985;121-132.
6. Blauer K.L., Poth M., Rogers W.M., Bernton E.W. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology. 129:1991;3174-3179.
7. Carlson L.E., Sherwin B.B. Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women. Neurobiol. Aging. 20:(3):1999;315-324.
8. Carlson L.E., Ursuliak Z., Goodey E., Angen M., Speca M. The effects of a mindfulness meditation based stress reduction program on mood and symptoms of stress in cancer outpatients: six month follow-up. Support. Care Cancer. 9:(2):2001;112-123.
9. Carlson, L.E., Speca, M., Patel, K.D., Goodey, E., in press. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and immune parameters in breast and prostate cancer outpatients. Psychosom. Med.
10. Cassileth B.R., Chapman C.C. Alternative and complementary cancer therapies. Cancer. 77:(6):1998;1026-1034.
11. Cassileth B.R., Lusk E.J., Brown L.L., Cross P.A. Psychosocial status of cancer patients and next of kin: normative data from the profile of mood states. J. Psychosoc. Oncol. 3:(3):1985;99-105.
12. Cohen S., Williamson G.M. Stress and infectious diseases in humans. Psychol. Bull. 109:1991;5-24.
13. Cos S., Fernandez R., Guezmes A., Sanchez-Barcelo E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 58:1998;4383-4390.
14. Courneya K.S. Exercise interventions during cancer treatment: biopsychosocial outcomes. Exerc. Sport Sci. Rev. 29:(2):2001;60-64.
15. Courneya K.S., Friedenreich C.M. Physical exercise and quality of life following cancer diagnosis: a literature review. Ann. Behav. Med. 21:(2):1999;171-179.
16. Cruess D.G., Antoni M.H., Kumar M., Ironson G., McCabe P., Fernandez J.B., Fletcher M., Schneiderman N. Cognitive-behavioral stress management buffers decreases in dehydroepiandrosterone sulfate (DHEAS) and increases in the cortisol/DHEAS ratio and reduces mood disturbance and perceived stress among HIV-seropostive men. Psychoneuroendocrinology. 24:1999;537-549.
17. Cruess D.G., Antoni M.H., McGregor B.A., Kilbourn K.M., Boyers A.E., Alferi S.M., Carver C.S., Kumar M. Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom. Med. 62:(3):2000;304-308.
18. Deepak K.K., Manchanda S.K., Maheshwari M.C. Meditation improves clinicoelectroencephalographic measures in drug-resistant epileptics. Biofeedback Self Regul. 19:(1):1994;25-40.
19. DeFlorio M., Masie M.J. Review of depression in cancer: gender differences. Depression. 3:1995;66-80.
20. Derogatis L.R., Morrow G.R., Fetting J. The prevalence of psychiatric disorders among cancer patients. J. Am. Med. Assoc. 249:1983;751-757.
21. Dorgan J.F., Stanczyk F.Z., Longcope C., Stephenson H.E. Jr., Chang L., Miller R., Franz C., Falk R.T., Kahle L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 6:(3):1997;177-181.
22. Ernst E., Cassileth B.R. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 83:1998;777-782.
23. Esterling B.A., Kiecolt-Glaser J.K., Glaser R. Psychosocial modulation of cytokine-induced natural killer cell activity in older adults. Psychosom. Med. 58:(3):1996;264-272.
24. Feldman H.A., Johannes C.B., Araujo A.B., Mohr B.A., Longcope C., McKinlay J.B. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am. J. Epidemiol. 153:(1):2001;79-89.
25. Friedenreich C.M., Courneya K.S., Bryant H.E. Relation between intensity of physical activity and breast cancer risk reduction. Med. Sci. Sports Exerc. 33:(9):2001;1538-1545.
26. Glaser J.L., Brind J.L., Vogelman J.H., Eisner M.J., Dillbeck M.C., Wallace R.K., Chopra D., Orentreich N. Elevated serum dehydroepiandrosterone sulfate levels in practitioners of the Transcendental Meditation (TM) and TM-Sidhi programs. J. Behav. Med. 15:(4):1992;327-341.
27. Gordon G.B., Bush T.L., Helzlsouer K.J., Miller S.R., Comstock G.W. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone-sulfate to the risk of developing postmenopausal breast cancer. Cancer Res. 50:1990;3859-3862.
28. Guazzo E.P., Kirkpatrick P.J., Goodyer I.M., Shiers H.M., Herbert J. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J. Clin. Endocrinol. Metab. 81:(11):1996;3951-3960.
29. Henderson L.E. Characteristics and Immune Function of Meditators and Non-Meditators: An Exploratory Study. 1989;University of Calgary.
30. Heuser I.F., Deuschle M.F., Luppa P.F., Schweiger U.F., Standhardt H.F., Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J. Clin. Endocrinol. Metab. 83:(9):1998;3130-3133.
31. Hornsby P.J. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann. N. Y. Acad. Sci. 774:1995;29-46.
32. Johannes C.B., Stellato R.K., Feldman H.A., Longcope C., McKinlay J.B. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. J. Clin. Epidemiol. 52:(2):1999;95-103.
33. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen. Hosp. Psychiatry. 4:1982;33-42.
34. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of your Body and Mind to face Stress, Pain and Illness. 1990;Delacourt, New York.
35. Kabat-Zinn J., Lipworth L., Burney R., Sellers W. Four-year follow-up of a meditation based program for the self-regulation of chronic pain: treatment outcomes and compliance. Clin. J. Pain. 2:1987;159-173.
36. Kabat-Zinn J., Massion A.O., Kristeller J., Peterson L.G., Fletcher D.E., Pbert O., Lenderking W.R., Santorelli S.F. Effectivenes of a meditation-based stress reduction program in the treatment of anxiety disorders. Am. J. Psychiatry. 149:(7):1992;943-963.
37. Kabat-Zinn J., Wheeler E., Light T., Skillings A., Scharf M.J., Croplwy T.G., Hosmer D., Bernhard J.D. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to sever psoriasis undergoing phototherpay (UVB) and photochemotherapy (PUVA). Psychosom. Med. 60:1998;625-632.
38. Kailajarvi M.F., Ahokoski O.F., Virtanen A.F., Salminen E.F., Irjala K. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids. Anticancer Res. 20:(2B):2000;1323-1327.
39. Kanno J., Wakikawa A., Utsuyama M., Hirokawa K. Effect of restraint stress on immune system and experimental B melanoma metastasis in aged mice. Mech. Ageing Dev. 93:(1-3):1997;107-117.
40. Kaplan K.H., Goldenberg D.L., Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen. Hosp. Psychiatry. 15:(5):1993;284-289.
41. Keller M., Henrich G. Ilness-related distress: does it mean the same for men and women? Acta Oncol. 38:(6):1999;747-755.
42. Kirschbaum C., Hellhamer D.H. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology. 19:1994;313-333.
43. Laakso M.L., Porkka-Heiskanen T.F., Alila A.F., Stenberg D.F., Johansson G. Correlation between salivary and serum melatonin: dependence on serum melatonin levels. J. Pineal Res. 9:(1):1990;39-50.
44. Leckie M.S., Thompson E. Symptoms of Stress Inventory. 1979;University of Washington, Seattle, WA.
45. Liebmann P.M., Wolfler A., Hofer D., Schauenstein K. Melatonin and immune system. Arch. Allergy Immunol. 112:1997;203-211.
46. Lissoni P., Cazzaniga M., Tancini G., Scardino E., Musci R., Barni S., Maffezzini M., Meroni T., Rocco F., Conti A., Maestroni G. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur. Urol. 31:1997;178-181.
47. Lissoni P., Barni S., Mandala M., Ardizzoia A., Paolorossi F., Vaghi M., Longarini R., Malugani F., Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur. J. Cancer. 35:(12):1999a;1688- 1692.
48. Lissoni P., Tancini G., Paolorossi F., Mandala M., Ardizzoia A., Malugani F., Giani L., Barni S. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J. Pineal Res. 26:(3):1999b;169-173.
49. Lonning P.E., Johannessen D.C., Lien E.A., Ekse D., Fotsis T., Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 52:(5):1995;491-496.
50. MacLean C.R., Walton K.G., Wenneberg S.R., Levitsky D.K., Mandarino J.P., Waziri R., Schneider R.H. Altered responses of cortisol, GH, TSH and testosterone to acute stress after four months' practice of transcendental meditation (TM). Ann. N. Y. Acad. Sci. 746:1994;381-384.
51. Majewska M.D. Neuronal action of dehydroepiandrosterone: possible roles in brain development, aging, memory and affect. Ann. N. Y. Acad. Sci. 774:1995;111-120.
52. Massion A.O., Hebert J.R., Wertheimer M.D., Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med. Hypotheses. 44:1995;39-46.
53. Mazat L., Lafont S., Berr C., Debuire B., Tessier J.F., Dartigues J.F., Baulieu E.E. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc. Natl. Acad. Sci. U.S.A. 98:(14):2001;8145-8150.
54. McEwen B.S., Sapolsky R.M. Stress and cognitive function. Curr. Opin. Neurobiol. 5:(2):1995;205-216.
55. McIntyre I.M., Norman T.R., Burrows G.D., Armstrong S.M. Melatonin rhythm in human plasma and saliva. J. Pineal Res. 4:(2):1987;177-183.
56. McNair D.A., Lorr M., Droppelman L.F. Profile of Mood States. 1971;Educational and Industrial Testing Service, San Diego.
57. Michelson H., Bolund C., Nilsson B., Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30 - reference values from a large sample of Swedish population. Acta Oncol. 39:(4):2000;477-484.
58. Miller J.J., Fletcher K., Kabat-Zinn J. Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen. Hosp. Psychiatry. 17:1995;192-200.
59. Morales A.J., Nolan J.J., Jerald C., Nelson S., Yen S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78:(6):1994;1360-1367.
60. Mormont M.C., Levi F. Circadian-system alterations during cancer processes: a review. Int. J. Cancer. 70:(2):1997;241-247.
61. National Cancer Institute of Canada, 2001. Canadian Cancer Statistics 2001. Toronto, Ontario: National Cancer Institute of Canada.
62. Reibel D.K., Greeson J.M., Brainard G.C., Rosenzweig S. Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen. Hosp. Psychiatry. 23:(4):2001;183-192.
63. Riska E., Ettorre E. Mental distress: gender aspects of symptoms and coping. Acta Oncol. 38:(6):1999;757-761.
64. Schedlowski M., Jung C., Schimanski G., Tewes U., Schedlowski M., Schmoll H.-J. Effects of behavioral intervention on plasma cortisol and lymphocytes in breast cancer patients: an exploratory study. Psycho-Oncology. 3:1994;181-187.
65. Schneider R.H., Staggers F., Alexander C.N., Sheppard W., Rainforth M., Kondwani K., Smith S., King C.G. A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension. 26:(5):1995;820-827.
66. Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92:(12):2000;944-1000.
67. Shirtcliff E.A., Granger D.A., Schwartz E., Curran M.J. Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. Psychoneuroendocrinology. 26:(2):2001;165-173.
68. Sikes C.R.A., Lasley B.J. Cognitive sequelae of hypothalamic-pituitary- adrenal (HPA) dysregulation in depression. Biol. Psychiatry. 25:1989;148A-149A.
69. Singh B.B., Berman B.M., Hadhazy V.A., Creamer P. A pilot study of cognitive behavioral therapy in fibromyalgia. Altern. Ther. Health Med. 4:(2):1998;67-70.
70. Speca M., Carlson L.E., Goodey E., Angen M. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom. Med. 62:(5):2000;613-622.
71. Spiegel D. Cancer and depression. Br. J. Psychiatry Suppl. (30):1996;109-116.
72. Spiegel D., Sephton S.E., Terr A.I., Sittes D.P. Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways. Ann. N. Y. Acad. Sci. 840:1998;674-683.
73. Strain J.J. Adjustment disorders. Holland J.F. Psycho-oncology. 1998;509-517 Oxford University Press, New York.
74. Sudsuang R., Chentanez V., Veluvan K. Effect of Buddhist meditation on serum cortisol and total protein levels, blood pressure, pulse rate, lung volume and reaction time. Physiol. Behav. 50:(3):1991;543-548.
75. Tamarkin L., Danforth D., Lichter A., DeMoss E., Cohen M., Chabner B., Lippman M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 216:(4549):1982;1003-1005.
76. Ticher A., Haus E., Ron I.G., Sackett-Lundeen L., Ashkenazi I.E. The pattern of hormonal circadian time structure (acrophase) as an assessor of breast-cancer risk. Int. J. Cancer. 65:(5):1996;591-593.
77. Tooley G.A., Armstrong S.M., Norman T.R., Sali A. Acute increases in night-time plasma melatonin levels following a period of meditation. Biol. Psychol. 53:(1):2000;69-78.
78. Touitou Y., Bogdan A., Levi F., Benavides M., Auzeby A. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Br. J. Cancer. 74:(8):1996;1248-1252.
79. Turner-Cobb J.M., Sephton S.E., Koopman C., Blake-Mortimer J., Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom. Med. 62:(3):2000;337-345.
80. van der Pompe G., Duivenvoorden H.J., Antoni M.H., Visser A., Hejinen C.J. Effectiveness of a short-term group psychotherapy program on endocrine and immune function in breast cancer patients: an exploratory study. J. Psychosom. Res. 42:(5):1997;453-466.
81. van der Pompe G.F., Antoni M.H., Heijnen C.J. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. Psychoneuroendocrinology. 21:(4):1996;361-374.
82. Vermeulen A. Dehydroepiandrosterone sulfate and aging. Ann. N. Y. Acad. Sci. 774:1995;121-127.
83. Vijayalaxmi, Thomas C.R. Jr., Reiter R.J., Herman T.S. Melatonin: from basic research to cancer treatment clinics. J. Clin. Oncol. 20:(10):2002;2575- 2601.
84. Voultsios A.F., Kennaway D.J., Dawson D. Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J. Biol. Rhythms. 12:(5):1997;457-466.
85. Walton K.G., Pugh N.D., Gelderloos P., Macrae P. Stress reduction and preventing hypertension: preliminary support for a psychoneuroendocrine mechanism. J. Altern. Complement. Med. 1:(3):1995;263-283.
86. Wolkowitz O.M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology. 3:(19):1994;233-255.
87. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., Ormiston S., Johnson R., Canick J., Brizendine L., Weingartner H. DHEA treatment of depression. Biol. Psychiatry. 41:1997;311-318.
88. Zabora J.R., Blanchard C.G., Smith E.D., Roberts C.S., Glajchen M., Sharp J.M., Brintzenhofeszoc K.M., Locher J.W., Carr E.W., Best-Castner S., Smith P.M., Dozier-Hall D., Polinsky M.L., Hedlund S.C. Prevalence of psychological distress among cancer patients across the disease continuum. J. Psychosoc. Oncol. 15:(2):1997;73-86.